Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2702 2022-11-08 08:17:36 |
2 format corrected. + 7 word(s) 2709 2022-11-09 02:45:36 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Romero-Garmendia, I.;  Garcia-Etxebarria, K. Host Genetics and Microbiota Interactions in Colorectal Cancer. Encyclopedia. Available online: https://encyclopedia.pub/entry/33507 (accessed on 25 June 2024).
Romero-Garmendia I,  Garcia-Etxebarria K. Host Genetics and Microbiota Interactions in Colorectal Cancer. Encyclopedia. Available at: https://encyclopedia.pub/entry/33507. Accessed June 25, 2024.
Romero-Garmendia, Irati, Koldo Garcia-Etxebarria. "Host Genetics and Microbiota Interactions in Colorectal Cancer" Encyclopedia, https://encyclopedia.pub/entry/33507 (accessed June 25, 2024).
Romero-Garmendia, I., & Garcia-Etxebarria, K. (2022, November 08). Host Genetics and Microbiota Interactions in Colorectal Cancer. In Encyclopedia. https://encyclopedia.pub/entry/33507
Romero-Garmendia, Irati and Koldo Garcia-Etxebarria. "Host Genetics and Microbiota Interactions in Colorectal Cancer." Encyclopedia. Web. 08 November, 2022.
Host Genetics and Microbiota Interactions in Colorectal Cancer
Edit

The role of microbiota in colorectal cancer has been studied since alterations in its composition were observed. In addition, there are more and more pieces of evidence that microbiota could be implicated in colorectal cancer progression. Thus, the components of the microbiota could be biomarkers for the diagnosis and prognosis of colorectal cancer. In addition, it is important to address how the microbiota interacts with the host and how the host shapes the microbiota, in order to understand the biological pathways and mechanisms involved in their relationship and the consequences of their interactions in colorectal cancer. 

colorectal cancer genetics genomics microbiota

1. Microbiota Involvement in CRC

1.1. Microbiota Composition

When microbiota is analyzed, bacterial composition is usually analyzed. The studies about the role of archaea, viruses, fungi, and parasites are scarcer, and their effect on the rest of the microbiota is less known. However, there are valuable studies that have contributed to the understanding of the diversity in the composition of the microbiota and the complex interactions between the different members of the microbiota.

1.2. Pathways and Biological Functions of the Microbiota

One of the most remarkable features of bacteria is the plasticity of their genomes. Thus, it is not enough to know what taxa are present in colorectal cancer (CRC), and it is necessary to know the biological functions that they can carry out. There have been technical limitations to studying the gene content of microbiota, but its study is increasingly feasible.
However, it must pointed out that microbiota is functionally redundant in healthy persons[1][2]. Although a lot of taxa carrying diverse genes can be found in the microbiota, those genes have similar functions[1][2]. That is, the composition of microbiota varies between individuals, but the biological functions present in the microbiota are conserved. Thus, it is necessary to elucidate if this functional redundancy is perturbed in CRC, and how. To study the bacterial genes present, they can either be indirectly inferred using the microbiota composition, or directly by whole-genome sequencing of bacterial content.
In a study where stools from adenoma, CRC, and healthy patients were analyzed, based on the bacterial content, the biological functions were inferred[3]. In this case, the pathways related to amino acids biosynthesis, fermentation (isobutanol, acetate, and lactate), glucose metabolism (gluconeogenesis, glycolysis, and glycogen biosynthesis and degradation), saturated fatty acids, reductive incomplete TCA, nitrate degradation and methanogenesis were different in CRC samples[3].
Moreover, when the left and right colon cancer were compared, since the microbiota had a different composition, the microbial pathways present were different[4]. In the case of left colon cancer, “L-lysine fermentation” and “cob(II)yrinate a,c-diamide biosynthesis I” pathways were predominant, while there was no significantly enriched function in right colon cancer[4].
One study analyzed the bacterial gene content of CRC and healthy stools[5]. There were no significant differences in KEGG pathways between the genes present in CRC and healthy stools, but two KEGG modules (leucine degradation and guanine nucleotide biosynthesis) were significantly enriched[5]. In addition, 12 orthologous gene groups were more abundant in CRC (e.g., “Glycine reductase”, “N-acetylornithine carbamoyltransferase”, and “Rrf2 family transcriptional regulator”), while 7 were less abundant (e.g., “Type IV pilus assembly protein PilF”, “Protein-serine/threonine kinase” and “Phosphatidylglycerophosphatase B”)[5].
In another work, the gene content from whole-genome sequencing data was assigned to protein families or domains, and some differences were found between CRC and healthy samples[6]. In the case of protein domains, 7 were more abundant in CRC samples, and those domains were related to bacterial invasion and adhesins; while 5 were reduced domains related to antibiotic resistance, bacteriophage maturation, and threonine biosynthesis[6]. In the case of protein families, one family was more abundant in CRC (associated with proline iminopeptidase) and the other less abundant (associated with threonine biosynthesis)[6].
Moreover, novel methods have been developed to cluster bacterial genes using their co-abundance and, therefore, to find consistently disturbed genes in CRC[7]. That approach was used to analyze publicly available datasets and in healthy samples, the largest co-abundant gene group was from Clostridia, while in CRC the origin of those genes was taxonomically more diverse[7]. In addition, the largest co-abundant genes cluster in CRC had genes involved in the “metabolism of glycine/sarcosine/betaine”, “protection from the biochemical damage induced by reactive oxygen species”, “uptake of p-aminobenzoyl-glutamate”, and “transporters responsible for importing iron”, biological functions that are related to cancer progression[7].
To sum up, the studies where the biological capabilities of bacteria are analyzed are fewer than the ones analyzing the content, and few pathways or biological functions have been detected to be different in CRC. In accordance with the functional redundancy of microbiota, although the taxa present can change, the main functions of microbiota seem to be conserved and few pathways related to cancer progression can be detected.

2. Interactions between Host Genetics and Microbiota in CRC

The researchers have recapitulated some of the changes that have been observed, both in composition and biological functions in microbiota. However, is the host somewhat driving those changes, or does the microbiota change the host cells?
How host genetics shapes microbiota composition and microbiota the biological functions of the host have been intriguing questions. Over the years, their study has evolved, and it has not been until recently that the researchers have had a more precise picture of the genetic mechanisms that shape the host–microbiota interactions. The development of omics approaches has facilitated the analysis and inference of correlations and interactions between the host genetics (and its different layers) and microbiota. Although the number of such studies is scarce, the results of those studies have highlighted that there are some mechanisms shared by host genetics and microbiota, and other mechanisms that are independent.

2.1. Shared Risk Components

2.1.1. Genetic Variation

The study of the genetic variants of the host that affect the abundance of bacterial taxa has been a valuable asset to get genetic signatures related to microbiota composition[8]. Based on those genetic signatures of microbiota composition, it has been analyzed the contribution of various phyla to CRC risk using Mendelian Randomization analyses[9]. Although it is an indirect method, it gives information to determine if there are shared genetic mechanisms to CRC risk and the abundance of a given phylum. Although the results were weak, the genetic variants associated with the abundance of Firmicutes and Cyanobacteria phyla were also associated with the genetic risk of CRC, specifically with the genetic risk of left colon cancer[9]. It must pointed out that in the study in question, the genetic variants involved in total cholesterol levels were determined to be a risk factor in left colon cancer[9]. Thus, it cannot be ruled out that modifiable risk factors such as cholesterol levels could shape the risk of CRC through the host genetic and/or microbiota composition.
As mentioned previously, strains of E. colipks+ have been involved in CRC risk. The pks pathogenic island carries genes involved in colibactin, a genotoxic that could cause mutations in host cells[10]. The long-term exposure of E. colipks+ causes a distinct mutational signature in organoids, showing a bias towards T to N substitution and a single T deletion at T homopolymers[10]. In fact, these two mutational signatures were enriched in CRC samples[10]. In addition, a study showed that the transplant of the microbiota of CRC patients to a mice model altered the DNA of the cells of the gut of the mice[11]. Thus, the microbiota could cause somatic mutations in host cells.

2.1.2. Transcription

Moreover, the effect of the genes expressed by the colonic mucosa and the composition of the microbiota in CRC patients have been analyzed, among other gastrointestinal diseases[12]. In that study, they observed in CRC a correspondence between the variability of gene expression of gut tissue and microbiota composition[12]. In addition, they detected three pathways that affected the composition of the gut microbiota in the three gastrointestinal diseases that were analyzed (CRC, inflammatory bowel disease, and irritable bowel syndrome), namely “Oxidative phosphorylation”, “RAC1 pathway” and “ERBB1 downstream pathway”; and 52 pathways specific to CRC[12]. For example, among those specific pathways, there was the Syndecan-1 pathway[12], a pathway previously associated with tumorigenic activity and that affects the abundance of Parvimonas and Bacteroides fragilis in CRC[12], bacterial taxa that are biomarkers of CRC due to their role in the carcinogenesis. Regarding gene expression and taxa associations, the effect of the expression of 745 genes in the abundance of 120 microbes was found and those genes of the host were involved in tumor growth, progression, and metastasis[12].
Previously, the researchers have discussed the higher presence of Fusobacteria in certain subtypes of CRC[13]. When the expression of genes of the host tissue was analyzed to compare the expression pattern in the presence or absence of Fusobacteria, pathways of the host related to inflammatory-related signaling (e.g., “IL-8 signaling” or “Th17 activation”), “aryl hydrocarbon receptor (AhR) signaling”, cellular organization, movement and invasion pathways, and metabolic pathways (e.g., cholesterol and proteoglycan metabolism) were affected[13]. In that study, the role of Fusobacteria in CRC was experimentally analyzed and it was observed that Fusobacteria has protumorigenic effects[13]. The formate produced by Fusobacteria activates AhR signaling, which can lead to tumor invasion, activating proinflammatory profiles[13]. That is, a bacterial metabolite affects the expression of host cells and affects CRC progression.
Moreover, a study analyzed publicly available data to determine if the composition of microbiota affected host gene expression in early-stage CRC and advanced-stage CRC[14]. The bacterial taxa with more connections with the expression of host genes in early-stage CRC were Ilumatobacter, Rhodospirillum, and Nitrosospira, while in advanced-stage CRC they were Desulfurella, Nitriliruptor, and Jeotgalicoccus[14]. Indeed, these taxa are not the usual taxa associated with CRC. Thus, this kind of novel approach is useful to unveil hidden biological mechanisms. In addition, the connected genes with these bacteria belonged to biological functions related to proliferation, biogenesis, and cell cycles in early-stage CRC, and related to migration and angiogenesis in advanced-stage CRC[14].

2.1.3. Methylation

Another study analyzed the role of the microbiota in the methylation patterns of tumor suppressor genes[15], since their deregulation is one of the characteristics of CRC progression. The abundance of Hungatella hathewayi showed a correlation with the methylation level of tumor suppressor genes such as SOX11, THBD, SFRP2, GATA5, and ESR1; and Fusobacterium nucleatum with the methylation levels of MTSS1, RBM38, PKD1, and PTPRT[15]. In the case of the well-known tumor suppressor genes in CRC, MLH1, APC, PTEN, and CDX2 showed correlations with bacterial taxa[15]. Specifically, H. hathewayi abundance was correlated with CDX2, Streptococcus spp. with MLH1, and both taxa with APC[15]. In addition, using an experimental approach, the upregulation of DNA methyltransferase in host cells by F. nucleatum and H. hathewayi was observed[15].
Moreover, the transplant of the microbiota of CRC patients to a mice model showed that the methylation patterns in the mice cells change and those changes were enriched in genes involved in cell growth, signal transduction, nucleic acid binding, protein synthesis, channels, and carrier proteins[11]. Then, the methylation status of several genes in samples of the original CRC patients was analyzed, and the combination of some of them was able to discriminate between CRC patients and healthy controls[11]. In addition, the samples with higher methylation changes showed a higher abundance of Parvimonas[11].

2.1.4. Metabolites

In the case of the relationship between fecal microbiota and the metabolome, both layers were able to discriminate CRC samples from adenoma and healthy controls[3]. In addition, several genera were correlated with metabolites from the fecal microbiota[3]: Cholesteryl esters and sphingomyelins metabolites were positively correlated with the abundance of Fusobacterium, Gemella, Parvimonas, Peptrostreptococcus, and Erysipelotrichaceae, while negatively with Coprococcus, Dorea and Blautia. In the case of diacylphosphatidylcholines, they were negatively associated with Coprococcus, Dorea, and Blautia; and triacylglycerol metabolites were negatively correlated with Desulfovibrio and Synergistes genera[3]. Based on those results, a model to discriminate between adenomas, CRC, and healthy patients was developed[3].
It must be pointed out that the metabolites of the microbiota could interact with host cells’ through cell receptors. One study analyzed the metabolites present in the murine gut, and some of them were further investigated. It was observed that some metabolites derived from microbiota were able to activate pathways in human cell models[16]. This kind of interaction should be further studied in CRC, to determine if the microbiota interacts with host cells in this way and leads to the development of CRC.

2.1.5. Multilevel

Although the effect of the microbiota in the fecal metabolome in adenomas and CRC was established[3], the effect of host genetics was further studied[17]. In the case of the shared risk component, it was detected that the genetic variants associated with the abundance of Bacteroidetes and Firmicutes were also involved in adenoma or CRC genetic risk[17]. In addition, genetic variants associated with cholesterol, triglycerides, phosphatidylethanolamine, and phingomyelin metabolites were associated with adenoma or CRC genetic risk[17]. There were also detected interactions between host genes of pathways related to cholesterol metabolism and the effect of genetic variants related to HDL cholesterol in adenoma and CRC risk[17]. As previously mentioned[9], the interplay between host genetic factors, host lifestyle, and microbiota could shape the risk to develop adenomas and CRC.

2.2. Independent Risk Components

One study analyzed the role of bacterial toxins in pre-tumorous and tumorous tissue and the effect of host genetics in CRC[18]. The results showed that the cif toxin gene was more present in pre-cancerous polyps or adenomas, toxins of Escherichia coli were more abundant in adenocarcinomas, and E. colipks+ strains were a risk factor for CRC[18]. Interestingly, polygenic risk scores were used to measure the genetic risk of developing CRC in those patients, and there was not any significant difference between patients with pre-tumorous and tumorous lesions, and healthy individuals[18]. Thus, the host genetics did not influence the bacterial toxins and their role in the development of the lesions[18].
Previously, the researchers have discussed some examples of shared risk components of host genetics, the fecal metabolome, and microbiota[17]. However, when the three layers were analyzed altogether using multi-omic integration procedures, the variance of risk to adenoma and CRC explained by each layer was different[17]: microbiota had more weight in the variance, metabolome had less weight, and the contribution of host genetics was limited. Except for the factors that explained more variance, where microbiota and metabolome showed covariance, covariance was not detected in the rest of the factors[17]. Thus, when all the information of omic layers is used to analyze their involvement in adenoma and CRC risk, their contribution to adenoma or CRC risk was independent[17]. In fact, the models built to predict adenoma and CRC risk based on microbiota and the metabolome[17] were more robust when information from the three layers (host genetics, microbiota, and metabolome) was used, a fact which strengthens the idea that each layer captures part of the risk to CRC. That is to say, the information is not redundant[17] (Table 1).
Table 1. Summary of the findings about host–microbiota interactions in colorectal cancer.
As the researchers have reviewed, there are biological mechanisms that are involved in both genetic CRC risk and microbiota composition, but not all the role of microbiota in CRC is influenced by the genetics of the host. It must pointed out that the composition of the microbiota is influenced by diet[20] or lifestyle[21]. Therefore, the host could shape the composition of the microbiota by modifiable risk factors rather than genetic factors and that could partially explain that there are shared and independent risk factors. For example, the metabolism of cholesterol is one consistent pathway altered, an alteration that could partially be due to the host genetic component and another part of the diet. In addition, bacteria can shape the function of the host cell, by changing the expression and methylation patterns of key genes in CRC development.

References

  1. Sara Vieira-Silva; Gwen Falony; Youssef Darzi; Gipsi Lima-Mendez; Roberto Garcia Yunta; Shujiro Okuda; Doris Vandeputte; Mireia Valles-Colomer; Falk Hildebrand; Samuel Chaffron; et al.Jeroen Raes Species–function relationships shape ecological properties of the human gut microbiome. Nature Microbiology 2016, 1, 16088-16088, 10.1038/nmicrobiol.2016.88.
  2. Andrés Moya; Manuel Ferrer; Functional Redundancy-Induced Stability of Gut Microbiota Subjected to Disturbance. Trends in microbiology 2016, 24, 402-413, 10.1016/j.tim.2016.02.002.
  3. Marc Clos-Garcia; Koldo Garcia; Cristina Alonso; Marta Iruarrizaga-Lejarreta; Mauro D’Amato; Anais Crespo; Agueda Iglesias; Joaquín Cubiella; Luis Bujanda; Juan Manuel Falcón-Pérez; et al. Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. Cancers 2020, 12, 1142, 10.3390/cancers12051142.
  4. Toru Miyake; Haruki Mori; Daiki Yasukawa; Zhang Hexun; Hiromitsu Maehira; Tomoyuki Ueki; Masatsugu Kojima; Sachiko Kaida; Hiroya Iida; Tomoharu Shimizu; et al.Masashi OhnoAkira AndohMasaji Tani The Comparison of Fecal Microbiota in Left-Side and Right-Side Human Colorectal Cancer. European Surgical Research 2021, 62, 248-254, 10.1159/000516922.
  5. Jun Yu; Qiang Feng; Sunny Hei Wong; Dongya Zhang; Qiao Yi Liang; Youwen Qin; Longqing Tang; Hui Zhao; Jan Stenvang; Yanli Li; et al.Xiaokai WangXiaoqiang XuNing ChenWilliam Ka Kei WuJumana Al-AamaHans Jørgen NielsenPia KiilerichBenjamin Anderschou Holbech JensenTung On YauZhou LanHuijue JiaJunhua LiLiang XiaoThomas Yuen Tung LamSiew Chien NgAlfred Sze-Lok ChengVincent Wai-Sun WongFrancis Ka Leung ChanXun XuHuanming YangLise MadsenChristian DatzHerbert TilgJian WangNils BrünnerKarsten KristiansenManimozhiyan ArumugamJoseph Jao-Yiu SungJun Wang Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 2015, 66, 70-78, 10.1136/gutjnl-2015-309800.
  6. Mark Loftus; Sayf Al-Deen Hassouneh; Shibu Yooseph; Bacterial community structure alterations within the colorectal cancer gut microbiome. BMC Microbiology 2021, 21, 1-18, 10.1186/s12866-021-02153-x.
  7. Samuel S. Minot; Amy D. Willis; Clustering co-abundant genes identifies components of the gut microbiome that are reproducibly associated with colorectal cancer and inflammatory bowel disease. Microbiome 2019, 7, 1-10, 10.1186/s40168-019-0722-6.
  8. Alexander Kurilshikov; Carolina Medina-Gomez; Rodrigo Bacigalupe; Djawad Radjabzadeh; Jun Wang; Ayse Demirkan; Caroline I. Le Roy; Juan Antonio Raygoza Garay; Casey T. Finnicum; Xingrong Liu; et al.Daria V. ZhernakovaMarc Jan BonderTue H. HansenFabian FrostMalte C. RühlemannWilliams TurpinJee-Young MoonHan-Na KimKreete LüllElad BarkanShiraz A. ShahMyriam FornageJoanna Szopinska-TokovZachary D. WallenDmitrii BorisevichLars AgreusAnna AndreassonCorinna BangLarbi BedraniJordana T. BellHans BisgaardMichael BoehnkeDorret I. BoomsmaRobert D. BurkAnnique ClaringbouldKenneth CroitoruGareth E. DaviesCornelia M. van DuijnLiesbeth DuijtsGwen FalonyJingyuan FuAdriaan van der GraafTorben HansenGeorg HomuthDavid A. HughesRichard G. IjzermanMatthew A. JacksonVincent W. V. JaddoeMarie JoossensTorben JørgensenDaniel KeszthelyiRob KnightMarkku LaaksoMatthias LaudesLenore J. LaunerWolfgang LiebAldons J. LusisAd A. M. MascleeHenriette A. MollZlatan MujagicQi QibinDaphna RothschildHocheol ShinSøren J. SørensenClaire J. StevesJonathan ThorsenNicholas J. TimpsonRaul Y. TitoSara Vieira-SilvaUwe VölkerHenry VölzkeUrmo VõsaKaitlin H. WadeSusanna WalterKyoko WatanabeStefan WeissFrank U. WeissOmer WeissbrodHarm-Jan WestraGonneke WillemsenHaydeh PayamiDaisy M. A. E. JonkersAlejandro Arias VasquezEco J. C. de GeusKatie A. MeyerJakob StokholmEran SegalElin OrgCisca WijmengaHyung-Lae KimRobert C. KaplanTim D. SpectorAndre G. UitterlindenFernando RivadeneiraAndre FrankeMarkus M. LerchLude FrankeSerena SannaMauro D’AmatoOluf PedersenAndrew D. PatersonRobert KraaijJeroen RaesAlexandra Zhernakova Large-scale association analyses identify host factors influencing human gut microbiome composition. Nature Genetics 2021, 53, 156-165, 10.1038/s41588-020-00763-1.
  9. Koldo Garcia-Etxebarria; Ane Etxart; Maialen Barrero; Beatriz Nafria; Nerea Miren Segues Merino; Irati Romero-Garmendia; Andre Franke; Mauro D’Amato; Luis Bujanda; Performance of the Use of Genetic Information to Assess the Risk of Colorectal Cancer in the Basque Population. Cancers 2022, 14, 4193, 10.3390/cancers14174193.
  10. Cayetano Pleguezuelos-Manzano; Jens Puschhof; Axel Rosendahl Huber; Arne van Hoeck; Henry M. Wood; Jason Nomburg; Carino Gurjao; Freek Manders; Guillaume Dalmasso; Paul B. Stege; et al.Fernanda L. PaganelliMaarten H. GeurtsJoep BeumerTomohiro MizutaniYi MiaoReinier van der LindenStefan van der ElstJ. C. AmbroseP. ArumugamE. L. BapleM. BledaF. Boardman-PrettyJ. M. BoissiereC. R. BoustredH. BrittainM. J. CaulfieldG. C. ChanC. E. H. CraigL. C. DaughertyA. de BurcaA. DevereauG. ElgarR. E. FoulgerT. FowlerP. Furió-TaríJ. M. HackettD. HalaiA. HamblinS. HendersonJ. E. HolmanT. J. P. HubbardK. IbáñezR. JacksonL. J. JonesD. KasperaviciuteM. KayikciL. LahnsteinL. LawsonS. E. A. LeighI. U. S. LeongF. J. LopezF. Maleady-CroweJ. MasonE. M. McDonaghL. MoutsianasM. MuellerN. MurugaesuA. C. NeedC. A. OdhamsC. PatchD. Perez-GilD. PolychronopoulosJ. PullingerT. RahimA. RendonP. Riesgo-FerreiroT. RogersM. RytenK. SavageK. SawantR. H. ScottA. SiddiqA. SieghartD. SmedleyK. R. SmithA. SosinskyW. SpoonerH. E. StevensA. StuckeyR. SultanaE. R. A. ThomasS. R. ThompsonC. TregidgoA. TucciE. WalshS. A. WattersM. J. WellandE. WilliamsK. WitkowskaS. M. WoodM. ZarowieckiK. Christopher GarciaJanetta TopRob J. L. WillemsMarios GiannakisRichard BonnetPhil QuirkeMatthew MeyersonEdwin CuppenRuben van BoxtelHans CleversGenomics England Research Consortium Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature 2020, 580, 269-273, 10.1038/s41586-020-2080-8.
  11. Iradj Sobhani; Emma Bergsten; Séverine Couffin; Aurélien Amiot; Biba Nebbad; Caroline Barau; Nicola De’Angelis; Sylvie Rabot; Florence Canoui-Poitrine; Denis Mestivier; et al.Thierry PédronKhashayarsha KhazaiePhilippe J. Sansonetti Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures. Proceedings of the National Academy of Sciences of the United States of America 2019, 116, 24285-24295, 10.1073/pnas.1912129116.
  12. Sambhawa Priya; Michael B. Burns; Tonya Ward; Ruben A. T. Mars; Beth Adamowicz; Eric F. Lock; Purna C. Kashyap; Dan Knights; Ran Blekhman; Identification of shared and disease-specific host gene–microbiome associations across human diseases using multi-omic integration. Nature Microbiology 2022, 7, 780-795, 10.1038/s41564-022-01121-z.
  13. Dominik Ternes; Mina Tsenkova; Vitaly Igorevich Pozdeev; Marianne Meyers; Eric Koncina; Sura Atatri; Martine Schmitz; Jessica Karta; Maryse Schmoetten; Almut Heinken; et al.Fabien RodriguezCatherine DelbrouckAnthoula GaigneauxAurelien GinolhacTam Thuy Dan NguyenLea GrandmouginAudrey Frachet-BourCamille Martin-GallausiauxMaria PachecoLorie Neuberger-CastilloPaulo MirandaNikolaus ZuegelJean-Yves FerrandManon GantenbeinThomas SauterDaniel Joseph SladeInes ThieleJohannes MeiserSerge HaanPaul WilmesElisabeth Letellier The gut microbial metabolite formate exacerbates colorectal cancer progression. Nature Metabolism 2022, 4, 458-475, 10.1038/s42255-022-00558-0.
  14. Irving Uriarte-Navarrete; Enrique Hernández-Lemus; Guillermo de Anda-Jáuregui; Gene-Microbiome Co-expression Networks in Colon Cancer. Frontiers in genetics 2021, 12, 617505, 10.3389/fgene.2021.617505.
  15. Xiaoxuan Xia; William Ka Kei Wu; Sunny Hei Wong; Dabin Liu; Thomas Ngai Yeung Kwong; Geicho Nakatsu; Pearlly S. Yan; Yu-Ming Chuang; Michael Wing-Yan Chan; Olabisi Oluwabukola Coker; et al.Zigui ChenYun Kit YeohLiuyang ZhaoXiansong WangWing Yin ChengMatthew Tak Vai ChanPaul Kay Sheung ChanJoseph Jao Yiu SungMaggie Haitian WangJun Yu Bacteria pathogens drive host colonic epithelial cell promoter hypermethylation of tumor suppressor genes in colorectal cancer. Microbiome 2020, 8, 1-13, 10.1186/s40168-020-00847-4.
  16. Gautham V. Sridharan; KyungOh Choi; Cory Klemashevich; Charmian Wu; Darshan Prabakaran; Long Bin Pan; Shelby Steinmeyer; Carrie Mueller; Mona Yousofshahi; Robert C. Alaniz; et al.Kyongbum LeeArul Jayaraman Prediction and quantification of bioactive microbiota metabolites in the mouse gut. Nature Communications 2014, 5, 5492, 10.1038/ncomms6492.
  17. Koldo Garcia-Etxebarria; Marc Clos-Garcia; Oiana Telleria; Beatriz Nafría; Cristina Alonso; Marta Iruarrizaga-Lejarreta; Andre Franke; Anais Crespo; Agueda Iglesias; Joaquín Cubiella; et al.Luis BujandaJuan Manuel Falcón-Pérez Interplay between Genome, Metabolome and Microbiome in Colorectal Cancer. Cancers 2021, 13, 6216, 10.3390/cancers13246216.
  18. Alfonso Piciocchi; Elena Angela Pia Germinario; Koldo Garcia Etxebarria; Silvia Rossi; Lupe Sanchez-Mete; Barbara Porowska; Vittoria Stigliano; Paolo Trentino; Andrea Oddi; Fabio Accarpio; et al.Gian Luca GraziGiovanni BrunoMassimo BonucciMassimo GiambenedettiPatrizia SpigagliaFabrizio BarbantiSlawomir OwczarekIda LuzziElisabetta DelibatoZaira MarocciaLorenza NisticòCarla FiorentiniMauro D’AmatoRoberta De AngelisAlessia Fabbri Association of Polygenic Risk Score and Bacterial Toxins at Screening Colonoscopy with Colorectal Cancer Progression: A Multicenter Case-Control Study. Toxins 2021, 13, 569, 10.3390/toxins13080569.
  19. Sambhawa Priya; Michael B. Burns; Tonya Ward; Ruben A. T. Mars; Beth Adamowicz; Eric F. Lock; Purna C. Kashyap; Dan Knights; Ran Blekhman; Identification of shared and disease-specific host gene–microbiome associations across human diseases using multi-omic integration. Nature Microbiology 2022, 7, 780-795, 10.1038/s41564-022-01121-z.
  20. Francesco Asnicar; Sarah E. Berry; Ana M. Valdes; Long H. Nguyen; Gianmarco Piccinno; David A. Drew; Emily Leeming; Rachel Gibson; Caroline Le Roy; Haya Al Khatib; et al.Lucy FrancisMohsen MazidiOlatz MompeoMireia Valles-ColomerAdrian TettFrancesco BeghiniLéonard DuboisDavide BazzaniAndrew Maltez ThomasChloe MirzayiAsya KhleborodovaSehyun OhRachel HineChristopher BonnettJoan CapdevilaSerge DanzanvilliersFrancesca GiordanoLudwig GeistlingerLevi WaldronRichard DaviesGeorge HadjigeorgiouJonathan WolfJosé M. OrdovásChristopher GardnerPaul W. FranksAndrew T. ChanCurtis HuttenhowerTim D. SpectorNicola Segata Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nature Medicine 2021, 27, 321-332, 10.1038/s41591-020-01183-8.
  21. Jack A Gilbert; Martin J. Blaser; J. Gregory Caporaso; Janet Jansson; Susan V. Lynch; Rob Knight; Current understanding of the human microbiome. Nature Medicine 2018, 24, 392-400, 10.1038/nm.4517.
More
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : ,
View Times: 315
Entry Collection: Gastrointestinal Disease
Revisions: 2 times (View History)
Update Date: 09 Nov 2022
1000/1000
Video Production Service